Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis

Darbepoietin alfa (NESP) is a new long-acting erythropoietin, with a half-life 3 times longer than the old epoietins. In the present study, we evaluated the efficacy of NESP in a group of children on hemodialysis. Seven children, five male and two female, with a mean age of 11.5±3 years and a mean weight of 34.1±11 kg, were enrolled in the study. All had been treated for at least 6 months with epoietin alfa at a mean dose of 106±76 IU/kg 3 times/week i.v. They were then given NESP at a mean dose of 1.59±1.19 μg/kg once a week i.v., according to the suggested conversion index (weekly epoietin alfa dose/200=weekly NESP dose). Anemia was evaluated at the end of a dialysis session. This was especially important for children less compliant with water restriction. Serum ferritin and percentage transferrin saturation (TSAT) were also monitored, as were dialysis efficacy (Kt/V), blood pressure, and heparin requirements. Before starting the new treatment, all patients had an adequate mean hemoglobin (Hb) level (11.19±1.7 g/dl) and an adequate iron status (TSAT 24.2±11.5, serum ferritin 220±105 mg/dl). Five of the seven patients were also treated with intravenous ferric gluconate (10–20 mg/kg per week). Six children were on antihypertensive treatment. After the 1st month of treatment, we observed an excessive increase inHb, 12.3±1.7 g/dl, (P<0.05), with severe hypertension in the youngest two patients (Hb >13 g/dl). A short discontinuation of the medication, followed by restarting at a decreased dosage, allowed us to continue with the treatment. At the 2nd month of follow-up, a mean plasma Hb level of 12.2±1.2 g/dl was observed, with a NESP mean dose of 0.79±0.4 μg/kg per week. Steady state was reached at 3 months, with a mean Hb of 11.8±1.4 g/dl and a mean NESP dose of 0.51±0.18 μg/kg per week (P<0.05). These results persisted at 6 months of follow-up; only one child had a persistent increase in platelet level (373,000 vs. 555,000). Dialysis efficiency and heparin requirements during dialysis did not change significantly. The high efficacy of NESP allowed a consistent reduction in dosage. The suggested conversion index does not appear to be correct for pediatric patients. Our experience suggests that in this population the correct dose could be 0.25–0.75 μg/kg per week. Hypertension was the only major side effect reported. The influence of NESP on platelet proliferation needs to be further investigated. The single weekly administration of NESP could be effective and beneficial for both patients and clinicians.